Literature DB >> 11900499

Long-term medical care of testicular cancer survivors.

David J Vaughn1, Gretchen A Gignac, Anna T Meadows.   

Abstract

Testicular cancer is the most common solid tumor diagnosed in men 20 to 35 years of age. Because of highly effective treatments that may include surgery, chemotherapy, and radiation therapy, most patients become long-term survivors. Health-related issues that confront testicular cancer survivors include the late medical effects of chemotherapy, the late relapse of disease, the development of second cancers, the effect of the disease and treatment on fertility, and the psychosocial consequences. This case-based discussion focuses on the primary care physician's evaluation and management of a long-term survivor of testicular cancer who was previously treated with surgery and chemotherapy.

Entities:  

Mesh:

Year:  2002        PMID: 11900499     DOI: 10.7326/0003-4819-136-6-200203190-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Renal cell carcinoma following testicular cancer: case report and literature review.

Authors:  Nathan Lawrentschuk; Dennis Gyomber; Damien M Bolton
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  Secondary malignancies across the age spectrum.

Authors:  Andrea K Ng; Lisa B Kenney; Ethel S Gilbert; Lois B Travis
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

3.  Testicular seminoma 16 years after treatment for CNS germinoma.

Authors:  Amit Maity; Hui-Kuo G Shu; Alexander R Judkins; Michael J Fisher; Lisa E A Dwyer-Joyce; David J Vaughn
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

4.  Smoking cessation in long-term survivors of germ cell tumour.

Authors:  Marcus Hentrich; Martin J Fegg; Stephanie Meiler; Christoph Jost; Arthur Gerl
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-02       Impact factor: 4.553

Review 5.  [Aftercare in testicular cancer is worthwhile. Recurrences are curable].

Authors:  T S Pottek; K-P Dieckmann
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

6.  Bilateral carcinoma in situ of the testis and cystic fibrosis transmembrane conductance regulator (CFTR) mutation in an azoospermic patient with late-onset 21beta-hydroxylase deficiency.

Authors:  L Foppiani; M Baffico; G Lando; C Cappi; P De Cassan; M C Patrosso; A Vitali; S Penco; M Giusti; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

7.  Late recurrences of germ cell malignancies: a population-based experience over three decades.

Authors:  J Oldenburg; G C Alfsen; H Waehre; S D Fosså
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

8.  Health profiles of 996 melanoma survivors: the M. D. Anderson experience.

Authors:  Charles Stava; Martha Beck; L Todd Weiss; Adriana Lopez; Rena Vassilopoulou-Sellin
Journal:  BMC Cancer       Date:  2006-04-18       Impact factor: 4.430

9.  Testicular cancer: a longitudinal pilot study on stress response symptoms and quality of life in couples before and after chemotherapy.

Authors:  Marrit A Tuinman; Harald J Hoekstra; Dirk Th Sleijfer; Joke Fleer; Damon J Vidrine; Ellen R Gritz; Josette E H M Hoekstra-Weebers
Journal:  Support Care Cancer       Date:  2006-08-31       Impact factor: 3.603

10.  Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse.

Authors:  N J van As; D C Gilbert; J Money-Kyrle; D Bloomfield; S Beesley; D P Dearnaley; A Horwich; R A Huddart
Journal:  Br J Cancer       Date:  2008-06-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.